Company Profile:

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company offers therapeutic and preventive agents for cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases; neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Recent News:

On October 21, 2020, the company announced that two phase III studies evaluating its investigational 15-valent pneumococcal conjugate vaccine, V114, met their primary immunogenicity objectives. The candidate elicited strong immune response for all 15 serotypes included in it.

On October 15, 2020, the U.S. Food and Drug Administration (FDA) has approved an expanded label for KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL).

The company will report third-quarter 2020 results on Oct 27, before market open. The company delivered a four-quarter earnings surprise of 12.66%, on average, according to Zacks Equity Research.

Fundamental Analysis:

Ninestocks analyzes several different financial aspects: Growth, Profitability, solvency and efficiency.

Growth – Measures the growth of both the company’s income statement and cash flow.

@@@@@

Profitability – Measures the historical price movement of the stock.

@@@@@

Solvency – Measures the solvency of the company based on several ratios.

@@@@@

Efficiency – Measures the strength and historic growth of a company’s return on invested capital.

@@@@@

Conclusion:

MRK’s strengths can be seen in its better growth and strong profitability compared with its peers. Its revenue and net income have increased over recent years. Technical indicators signal the bullish signs, as there is a bullish crossover in Stochastic oscillator, MACD is trying to cross back up and the RSI stands at 44.62 with positive bias. We rate Merck & Co., Inc. (MRK) a STRONG BUY.